ST. HELIER, Jersey--(BUSINESS WIRE)--

Novocure (NASDAQ: NVCR) today announced that the results of research investigating the use of Tumor Treating Fields (TTFields) in multiple solid tumor types, both as a single agent and in combination with other cancer treatments, will be presented at this year’s American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC from April 1-5.

“The data being presented at AACR reinforce our commitment to studying TTFields across multiple solid tumors in order to fully understand its potential to improve efficacy without significantly increasing side effects when used in combination with other cancer treatments,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. “We believe our pre-clinical and clinical research demonstrates that TTFields’ mechanism of action affects fundamental aspects of cell division and may have broad applicability across a variety of solid tumors.”

The listing of TTFields clinical abstracts and presentations at AACR include:

• (Abstract #CT007) Tumor Treating Fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM). Final results of a randomized, multi-center phase III trial. R. Stupp. Sunday, April 2, 3:00 p.m. – 5:00 p.m. ET. Location: Ballroom C, Level 3.
• (Abstract #CT130) PANOVA: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma. M. Benavides. Tuesday, April 4, 1:00 – 5:00 p.m. ET. Location: Poster section 33.
• (Abstract #CT135) INNOVATE: A phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma. I. Vergote. Tuesday, April 4, 1:00 – 5:00 p.m. ET. Location: Poster section 33.
• (Abstract #CT068) Tumor Treating Fields in patients with glioblastomas: evaluation of treatment responses using advanced MR imaging techniques. S. Chawla. Monday, April 3, 1:00 – 5:00 p.m. ET. Location: Poster section 33.
• (Abstract #CT071) LUNAR – A phase 3 trial of TTFields in combination with PD-1 inhibitors or docetaxel for second line treatment of non-small-cell lung cancer (NSCLC). U. Weinberg. Monday, April 3, 1:00 – 5:00 p.m. ET. Location: Poster section 33.
• (Abstract #CT160) Modeling long term survival outcomes in glioblastoma patients treated with TTFields plus temozolomide and temozolomide monotherapy. G. Guzauskas. Monday, April 3, 1:00 – 5:00 p.m. ET. Location: Poster section 33.
• (Abstract #CT161) METIS: A phase 3 study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC. M. Mehta. Monday, April 3, 1:00 – 5:00 p.m. ET. Location: Poster section 33.
• (Abstract #CT020) Rates and impact of combination immunotherapy with Tumor Treating Fields in a glioma cohort. Y. Odia. Tuesday, April 4, 8:00 a.m. – 12:00 p.m. ET. Location: Poster section 33.
• (Abstract #CT022) Long term survival in glioblastoma patients after Tumor Treating Fields (TTFields) therapy. A.M. Rulseh. Tuesday, April 4, 1:00 – 5:00 p.m. ET. Location: TBD.

The listing of TTFields pre-clinical and other research abstracts and presentations at AACR include:

• (Abstract #617) Evaluating the in-vitro effects of Tumor Treating Fields on T-cell responses. G. Diamant. Sunday, April 2, 1:00 – 5:00 p.m. ET. Location: Section 26.
• (Abstract #838) Effect of Tumor Treating Fields on cell proliferation and synergistic antitumor efficacy in combination with ionizing radiation. E. Kim. Sunday, April 2, 1:00 – 5:00 p.m. ET. Location: Section 39.
• (Abstract #900) Tumor Treating Fields (TTFields) affect human glioma cell migration, invasion and adherence properties in vitro. R.S. Schneiderman. Sunday, April 2, 1:00 – 5:00 p.m. ET. Location: Section 42.
• (Abstract #1504) Tumor Treating Fields (TTFields) interfere with biological key properties of glioma cells in vitro. M. Silginer. Monday, April 3, 8:00 a.m. – 12:00 p.m. ET. Location: Section 19.
• (Abstract #1569) Optimizing transducer array configuration for treatment of pancreatic cancer using Tumor Treating Fields (TTFields). A. Naveh. Monday, April 3, 8:00 a.m. – 12:00 p.m. ET. Location: Section 24.
• (Abstract #2138) Tumor Treating Fields downregulate the BRCA1/FA pathway genes leading to reduced DNA repair capacity, the inhibition of mitophagy and enhanced cell death. N. Karanam. Monday, April 3, 1:00 – 5:00 p.m. ET. Location: Section 6.
• (Abstract #2312) Feasibility study of a fractionation method in the treatment of Tumor Treating Fields. Y. Jo. Monday, April 3, 1:00 – 5:00 p.m. ET. Location: Section 13.
• (Abstract #3309) Tumor Treating Fields decrease proliferation and clonogenicity of patient-derived WHO grade IV glioma cell lines. S.K. Michelhaugh. Tuesday, April 4, 8:00 a.m. – 12:00 p.m. ET. Location: Section 13.
• (Abstract #3315) Cancer cells upregulate autophagy as a survival mechanism in response to Tumor Treating Fields (TTFields). Y. Porat. Tuesday, April 4, 8:00 a.m. – 12:00 p.m. ET. Location: Section 13.
• (Abstract #3665) Tumor Treating Fields (TTFields) plus anti-PD-1 therapy induce immunogenic cell death resulting in enhanced antitumor efficacy. T. Voloshin. Tuesday, April 4, 8:00 a.m. – 12:00 p.m. ET. Location: Section 27.
• (Abstract #3730) Early metabolic response to Tumor Treating Fields in patients with recurrent glioblastoma. S. Mittal. Tuesday, April 4, 8:00 a.m. – 12:00 p.m. ET. Location: Section 29.
• (Abstract #4528) A novel transducer array design optimizing TTFields delivery to the thorax. H.S. Hershkovich. Tuesday, April 4, 1:00 – 5:00 p.m. ET. Location: Section 24.
• (Abstract #4536) Using diffusion weighted imaging (DWI) data to accurately predict electric field delivery to the tumor during TTFields treatment. C. Wenger. Tuesday, April 4, 1:00 – 5:00 p.m. ET. Location: Section 24.
• (Abstract #5228) The impact of microtubules on solution conductance and capacitance; implications for the use of AC electric fields in cancer therapy. J.A. Tuszynski. Wednesday, April 5, 8:00 a.m. – 12:00 p.m. ET. Location: Section 9.

About Novocure

Novocure is an oncology company developing a profoundly different cancer treatment centered on a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2017, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006553/en/